Skip to main content

Advertisement

SpringerLink
Log in

Prognostic Role of microRNA-21 Expression in Brain Tumors: a Meta-analysis

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Many studies have shown that microRNAs have important roles in the development and progression of various cancers. Recent studies also showed that microRNA-21 expression may be associated with the prognosis of patients with several common cancers. However, there was still lack of evidence for the prognostic role of microRNA-21 expression in brain tumors. We performed a systemic review and meta-analysis of published and unpublished studies to assess the prognostic role of microRNA-21 expression in patients with brain tumors. PubMed, Embase, and Google Scholar databases were searched for eligible studies with data assessing the prognostic role of microRNA-21 expression in brain tumors. Pooled hazard ratios (HRs) of microRNA-21 expression for overall survival and 95 % confidence intervals (CI) were calculated. Six studies from five publications were finally included into the meta-analysis. Those six studies included a total of 747 patients with brain tumors and 654 patients with gliomas. For overall survival, the pooled HR of higher microRNA-21 expression in patients with brain tumors was 1.82 (95 % CI 1.29–2.58, P = 0.001). In patients with gliomas, the HR for overall survival of higher microRNA-21 expression was 1.83 (95 % CI 1.09–3.09, P = 0.023). Sensitivity analysis by omitting one study by turns also showed there was no obvious influence of individual study on the pooled HRs. There was no obvious risk of publication bias in the meta-analysis. The present meta-analysis suggests that microRNA-21 is associated with the prognosis of patients with brain tumors, and high expression of microRNA-21 can predict poor prognosis in patients with brain tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310(17):1842–1850

    Article  CAS  PubMed  Google Scholar 

  2. Jansen M, Yip S, Louis DN (2010) Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 9(7):717–726

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D et al (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15(9):e395–e403

    Article  PubMed  Google Scholar 

  4. Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ (2011) Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol 12(1):83–91

    Article  CAS  PubMed  Google Scholar 

  5. Ha M, Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15(8):509–524

    Article  CAS  PubMed  Google Scholar 

  6. Schwarzenbach H, Nishida N, Calin GA, Pantel K (2014) Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 11(3):145–156

    Article  CAS  PubMed  Google Scholar 

  7. Yoshino H, Seki N, Itesako T, Chiyomaru T, Nakagawa M, Enokida H (2013) Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol 10(7):396–404

    Article  CAS  PubMed  Google Scholar 

  8. Hermeking H (2012) MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 12(9):613–626

    Article  CAS  PubMed  Google Scholar 

  9. Sun K, Lai EC (2013) Adult-specific functions of animal microRNAs. Nat Rev Genet 14(8):535–548

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yang Y, Qian J, Chen Y, Pan Y (2014) Prognostic role of circulating microRNA-21 in cancers: evidence from a meta-analysis. Tumour Biol 35(7):6365–6371

    Article  CAS  PubMed  Google Scholar 

  11. Fu X, Han Y, Wu Y, Zhu X, Lu X, Mao F, Wang X, He X et al (2011) Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur J Clin Invest 41(11):1245–1253

    Article  CAS  PubMed  Google Scholar 

  12. Zhi F, Chen X, Wang S, Xia X, Shi Y, Guan W, Shao N, Qu H et al (2010) The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 46(9):1640–1649

    Article  CAS  PubMed  Google Scholar 

  13. Hermansen SK, Dahlrot RH, Nielsen BS, Hansen S, Kristensen BW (2013) MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. J Neurooncol 111(1):71–81

    Article  CAS  PubMed  Google Scholar 

  14. Wu L, Li G, Feng D, Qin H, Gong L, Zhang J, Zhang Z (2013) MicroRNA-21 expression is associated with overall survival in patients with glioma. Diagn Pathol 8200

  15. Barbano R, Palumbo O, Pasculli B, Galasso M, Volinia S, D’Angelo V, Icolaro N, Coco M et al (2014) A miRNA signature for defining aggressive phenotype and prognosis in gliomas. PLoS One 9(10):e108950

    Article  PubMed  PubMed Central  Google Scholar 

  16. Mao X, Sun Y, Tang J (2014) Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma. Neurol Sci 35(2):233–238

    Article  PubMed  Google Scholar 

  17. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012

    Article  CAS  PubMed  Google Scholar 

  18. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10(1):101–129

    Article  Google Scholar 

  19. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560

    Article  PubMed  PubMed Central  Google Scholar 

  20. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188

    Article  CAS  PubMed  Google Scholar 

  21. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748

    CAS  PubMed  Google Scholar 

  22. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Yang CH, Yue J, Pfeffer SR, Fan M, Paulus E, Hosni-Ahmed A, Sims M, Qayyum S et al (2014) MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3). J Biol Chem 289(36):25079–25087

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Li R, Li X, Ning S, Ye J, Han L, Kang C (2014) Identification of a core miRNA-pathway regulatory network in glioma by therapeutically targeting miR-181d, miR-21, miR-23b, beta-catenin, CBP, and STAT3. PLoS One 9(7):e101903

    Article  PubMed  PubMed Central  Google Scholar 

  25. Wang Q, Li P, Li A, Jiang W, Wang H, Wang J, Xie K (2012) Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res 3197

  26. Srinivasan S, Patric IR, Somasundaram K (2011) A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One 6(3):e17438

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L, Lzicarova E, Svoboda M et al (2011) MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci 102(12):2186–2190

    Article  CAS  PubMed  Google Scholar 

  28. Delfino KR, Serao NV, Southey BR, Rodriguez-Zas SL (2011) Therapy-, gender- and race-specific microRNA markers, target genes and networks related to glioblastoma recurrence and survival. Cancer Genomics Proteomics 8(4):173–183

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, Araki Y, Kuga D et al (2010) MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res 16(16):4289–4297

    Article  CAS  PubMed  Google Scholar 

  30. Sun H, Yin L, Li S, Han S, Song G, Liu N, Yan C (2013) Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis. J Neurooncol 113(2):277–284

    Article  CAS  PubMed  Google Scholar 

  31. Dong X, Liu RY, Chen WD (2014) Correlation of promoter methylation in the MGMT gene with glioma risk and prognosis: a meta-analysis. Mol Neurobiol

  32. Lv S, Sun B, Zhong X, Dai C, Wang W, Ma X, Song H, Shi R, et al. (2014) The clinical implications of chemokine receptor CXCR4 in grade and prognosis of glioma patients: a meta-analysis. Mol Neurobiol

  33. Yang X, Lv S, Liu Y, Li D, Shi R, Tang Z, Fan J, Xu Z (2014) The clinical utility of matrix metalloproteinase 9 in evaluating pathological grade and prognosis of glioma patients: a meta-analysis. Mol Neurobiol

  34. Zhao J, Ma W, Zhao H (2014) Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis. Neuro Oncol 16(1):103–112

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethical Standards

There was no funding for the study. The present study was a meta-analysis of relevant studies, and it did not involve human participants and/or animals. In addition, no informed consent was needed in the study.

Conflict of Interest

We declare that we have no conflicts of interest.

Author information

Author notes

    Authors and Affiliations

    1. Department of Oncology, Ganzhou People’s Hospital, Ganzhou, 341000, China

      Xiao-Yan He, Xiao-Qing Guo & Zhen-Yu Xiao

    2. Ganzhou Medical School, Ganzhou, 341000, China

      Yu-Dong Liao

    3. Department of Endocrinology and Metabolic Diseases, Affiliated Hospital of Qingdao University, Qingdao, 266006, China

      Robin Wang & Yan-Gang Wang

    Authors
    1. Xiao-Yan He
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Yu-Dong Liao
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Xiao-Qing Guo
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Robin Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Zhen-Yu Xiao
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Yan-Gang Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Zhen-Yu Xiao or Yan-Gang Wang.

    Additional information

    Xiao-Yan He, Yu-Dong Liao, and Xiao-Qing Guo contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    He, XY., Liao, YD., Guo, XQ. et al. Prognostic Role of microRNA-21 Expression in Brain Tumors: a Meta-analysis. Mol Neurobiol 53, 1856–1861 (2016). https://doi.org/10.1007/s12035-015-9140-3

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12035-015-9140-3

    Keywords

    Search

    Navigation